ALX Oncology to Host Virtual R&D Day on March 5, 2025
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) has announced a virtual Research and Development (R&D) Day scheduled for March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The event will provide comprehensive updates on the company's pipeline developments, with a particular focus on their lead investigational CD47-blocker evorpacept.
The virtual webcast will feature presentations from company leadership and external key opinion leaders, offering insights into clinical program progress along with business and financial updates. Interested participants can access the live webcast through the 'Investors' section of ALX Oncology's website under 'Events and Presentations,' with a replay available after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ALXO gained 7.27%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company leadership and external key opinion leaders to highlight clinical program progress and provide business and financial updates
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The virtual webcast event will focus on information and updates related to the company’s pipeline, lead investigational CD47-blocker evorpacept, as well as business and financial updates.
R&D Day Webcast Information
The ALX Oncology virtual R&D Day will be webcast live and a replay will be available after the event by visiting the “Investors” section of ALX Oncology’s website and selecting “Events and Presentations.”
Date & Time: Wednesday, March 5, 2025, 6:00 a.m. PT/9:00 a.m. ET
Webcast Access: https://edge.media-server.com/mmc/p/yfucf8t5
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577
FAQ
When is ALX Oncology (ALXO) hosting its R&D Day in 2025?
What will be discussed at ALXO's March 2025 R&D Day?
How can investors access ALXO's R&D Day presentation?
What is the main drug candidate being discussed at ALXO's R&D Day?
